Cargando…
Ginsenoside Rg3 and sorafenib combination therapy relieves the hepatocellular carcinomaprogression through regulating the HK2-mediated glycolysis and PI3K/Akt signaling pathway
Hepatocellular carcinoma (HCC) is the most common pathological type of primary hepatic carcinoma. This study investigated the effects of ginsenoside Rg3 (Rg3) and sorafenib (SFN) combination therapy on HCC progression. The HCC-related data were obtained from TCGA database, and the data of HK2 mRNA,...
Autores principales: | Wei, Qi, Ren, Yuan, Zheng, Xia, Yang, Sufang, Lu, Tingting, Ji, Hongyao, Hua, Haiqing, Shan, Kuizhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275937/ https://www.ncbi.nlm.nih.gov/pubmed/35719058 http://dx.doi.org/10.1080/21655979.2022.2074616 |
Ejemplares similares
-
Examination of Combined Treatment of Ginsenoside Rg3 and 5-Fluorouracil in Lung Adenocarcinoma Cells
por: Shan, Kuizhong, et al.
Publicado: (2022) -
Ginsenoside Rg3 in combination with artesunate overcomes sorafenib resistance in hepatoma cell and mouse models
por: Chen, Ying-Jie, et al.
Publicado: (2022) -
Ginsenoside Rg3 inhibits the malignant progression of cervical cancer cell by regulating AKT2 expression
por: Liu, Hui, et al.
Publicado: (2023) -
Ginsenoside Rg3 enhances the anticancer effect of 5-FU in colon cancer cells via the PI3K/AKT pathway
por: Hong, Shunzhong, et al.
Publicado: (2020) -
Antitumor activity of ginsenoside Rg3 in melanoma through downregulation of the ERK and Akt pathways
por: Meng, Lingbin, et al.
Publicado: (2019)